New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 13, 2013
13:17 EDTVPHM, SNY, SHPG, GSViroPharma hires Goldman to explore sale, Bloomberg says
ViroPharma (VPHM) has hired Goldman Sachs (GS) to explore a sale after receiving takeover interest from Sanofi (SNY) and Shire (SHPG), reports Bloomberg, citing people with knowledge of the process. Shares of ViroPharma traded sharply higher following initial headlines of the report, and are currently up better than 25% in afternoon trade. U.S.-listed shares of Shire are off their worst levels and have turned positive following the report, while Sanofi shares are little changed. Reference Link
News For VPHM;SNY;SHPG;GS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 16, 2014
16:29 EDTSHPGShire price target lowered to $198 from $278 at Leerink
Subscribe for More Information
15:59 EDTGSGoldman Sachs discussing possible acquisition of IndexIQ, Reuters reports
Goldman Sachs is in talks to acquire IndexIQ, an exchange-traded fund provider, Reuters reports, citing three sources familiar with the situation. Goldman would be able to introduce passively managed and actively-managed ETF's within months if they purchase IndexIQ, Reuters added. Reference Link
10:31 EDTGSGoldman CFO says would consider accretive acqusitions, but environment tough
Goldman Sachs CFO Schwartz says the regulatory environment makes it harder generally for all financial institutions to do deals, but that Goldman remains willing to consider a deal in any of its segments if the transaction would be accretive and a good fit.
10:18 EDTGSGoldman Sachs says liquidations contributed to market move over last two days
09:48 EDTGSGoldman Sachs CFO says yesterday 'painful' but global growth forecast unchanged
Subscribe for More Information
09:35 EDTGSGoldman Sachs CFO says investment banking backlog at highest level since 2007
Subscribe for More Information
09:34 EDTGSGoldman Sachs says global share of announced M&A 29%, up 300 bps from 2013
Goldman Sachs CFO Harvey Schwartz is speaking on the company's Q3 earnings conference call.
09:23 EDTGSOn The Fly: Pre-market Movers
Subscribe for More Information
08:52 EDTSHPGAbbVie price target lowered to $59 from $71 at BMO Capital
Subscribe for More Information
08:19 EDTSNYSanofi Pasteur, Immune Design enter collaboration HSV therapy
Immune Design (IMDZ) announced that it has entered into a broad collaboration for the development of a herpes simplex virus, or HSV, immune therapy with Sanofi Pasteur, the vaccines division of Sanofi (SNY). Sanofi Pasteur and Immune Design will each contribute product candidates to the collaboration: Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate. The collaboration will explore the potential of various combinations of agents, including leveraging Immune Design's GLAASTM platform, with the goal to select the best potential immune therapy for patients. The two companies will develop the products jointly through Phase 2 clinical trials, at which point Sanofi Pasteur intends to continue development of the most promising candidate and be responsible for commercialization. Sanofi Pasteur will bear the costs of all preclinical and clinical development, with Immune Design providing a specific formulation of GLA from the GLAAS platform at its cost through Phase 2 studies. Immune Design will be eligible to receive future milestone and royalty payments on any product developed from the collaboration; other financial terms of the agreement have not been disclosed.
07:40 EDTGSGoldman: Net provisions for litigation for Q3 $194M vs. $142M a year ago
Subscribe for More Information
07:40 EDTGSGoldman Sachs says total staff increased 3% during Q3
Subscribe for More Information
07:39 EDTGSGoldman CEO: Client activity driven by improving U.S. economic conditions
Subscribe for More Information
07:38 EDTGSGoldman Sachs reports Common Equity Tier 1 ratio 11.8% at September 30
Subscribe for More Information
07:36 EDTGSGoldman Sachs raises quarterly dividend to 60c per share
Subscribe for More Information
07:36 EDTGSGoldman Sachs reports Q3 EPS $4.57, consensus $3.21
Reports Q3 revenue $8.39B, consensus $7.85B.
06:17 EDTSHPGJefferies says Medtronic 'needs to do' Covidien takeover
Jefferies says it "can't see how Medtronic walks" from the Covidien (COV) takeover given how compelling the merger is. The firm confirmed with Medtronic (MDT) that nothing has changed in the company's commitment to the deal since new financing terms were announced on October 3. In Jefferies view, "Medtronic needs to do this deal." It notes the spread on the acquisition widened significantly on the news that Abbvie (ABBV) is reconsidering its acquisition of Shire (SHPG).
05:50 EDTSHPGStocks with implied volatility movement; SHPG SIRI
Subscribe for More Information
05:37 EDTSHPGShire releases statement regarding AbbVie withdrawal of recommendation
Subscribe for More Information
05:21 EDTSHPGAbbVie recommends holders vote against Shire transaction
Following Shire's (SHPG) waiver of the three-day notice period, AbbVie (ABBV) announces its board withdraws its recommendation made on July 18 regarding the proposed Shire transaction and recommends that stockholders vote against the transaction. AbbVie and its board made this determination following a detailed consideration of the impact of the U.S. Department of Treasury's unilateral changes to the tax rules, as issued on September 22. The breadth and scope of the changes, including the unexpected nature of the exercise of administrative authority to impact longstanding tax principles, and to target specifically a subset of companies that would be treated differently than either other inverted companies or foreign domiciled entities, introduced an unacceptable level of uncertainty to the transaction. Additionally, the changes eliminated certain of the financial benefits of the transaction, most notably the ability to access current and future global cash flows in a tax efficient manner as originally contemplated in the transaction. This fundamentally changed the implied value of Shire to AbbVie in a significant manner. Under the conditions of AbbVie's offer and the terms of the Co-operation Agreement, the withdrawal of the recommendation alone will not cause a lapse of AbbVie's offer or terminate the Co-operation Agreement between AbbVie and Shire. Unless Shire and the U.K. Takeover Panel agree otherwise, AbbVie must convene an AbbVie stockholder meeting to consider the adoption of the U.S. merger agreement. AbbVie's offer will lapse if the company's stockholders do not adopt the agreement. Assuming Shire provides the requisite cooperation and consents, a pre-effective amendment to the registration statement filed by AbbVie Private Limited in connection with the combination is expected to be filed with the SEC as soon as practicable. Under the terms of the Co-operation Agreement, following the withdrawal of the AbbVie Board of Directors' recommendation, a break fee of approximately $1.64B will be payable to Shire if either: AbbVie stockholders do not approve the adoption of the U.S. merger agreement at an AbbVie stockholder meeting; or such a meeting does not occur by December 14.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use